Cancer Cachexia Pipeline report embraces in-depth Cancer Cachexia commercial assessment and clinical assessment of the products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cancer Cachexia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/cancer-cachexia-pipeline-insight
Several pharmacological and nutritional approaches have been used for the treatment of cancer cachexia. Keeping in mind that both anorexia and metabolic disturbances are involved, the development of different therapeutic strategies has focused on two major factors, namely, improving appetite and neutralizing metabolic disturbances.
The dynamics of the cancer cachexia market is anticipated to change in the coming years owing to the positive outcomes of some of the rare candidates during the developmental stage by key pharma players.
Some of the key players in the cachexia market includes:
Helsinn Healthcare
Actimed Therapeutics
Artelo Biosciences
NGM Biopharmaceuticals
And many others.
Drugs Covered in the Cancer Cachexia Pipeline Report
Anamorelin
MT‐102 (Espindolol)
ART27.13
NGM120
And many others
The launch of emerging therapies is expected during the forecast period of 2020–2030.
Cancer Cachexia Pipeline Assessment
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Cancer Cachexia with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Cancer Cachexia treatment.
-
Cancer Cachexia key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Cancer Cachexia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Scope of the report
-
The Cancer Cachexiareport provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Cancer Cachexia across the complete product development cycle, including all clinical and nonclinical stages.
-
It comprises of detailed profiles of Cancer Cachexia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
-
Detailed Cancer Cachexia research and development progress and trial details, results wherever available, are also included in the pipeline study.
-
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Cancer Cachexia.
Report highlights
A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Cancer Cachexia.
In the coming years, the Cancer Cachexia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics that are working to assess challenges and seek opportunities that could influence Cancer Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
A detailed portfolio of major pharma players who are involved in fueling the Cancer Cachexia treatment market. Several potential therapies for Cancer Cachexia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Cancer Cachexia market size in the coming years.
Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Cancer Cachexia) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Table of Content
1. Report Introduction
2. Cancer Cachexia
3. Cancer Cachexia Current Treatment Patterns
4. Cancer Cachexia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Cancer Cachexia Late Stage Products (Phase-III)
7. Cancer Cachexia Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cancer Cachexia Discontinued Products
13. Cancer Cachexia Product Profiles
14. Cancer Cachexia Key Companies
15. Cancer Cachexia Key Products
16. Dormant and Discontinued Products
17. Cancer Cachexia Unmet Needs
18. Cancer Cachexia Future Perspectives
19. Cancer Cachexia Analyst Review
20. Appendix
21. Report Methodology
Related Reports
Cancer Cachexia (CC) Market Insights, Epidemiology, and Market Forecast—2030
DelveInsight’s ‘Cancer Cachexia (CC) – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Cancer Cachexia (CC), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Cancer Cachexia (CC) Epidemiology Forecast—2030
DelveInsight’s ‘Cancer Cachexia (CC)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Cancer Cachexia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/